Drug Profile
Calcitonin intranasal - Bausch Health Companies
Alternative Names: Calcitonin Intranasal; Calcitonina Hubber; Oseum; Salcatonin intranasal - Bausch Health CompaniesLatest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator Valeant Pharmaceuticals International
- Developer Bausch Health Companies
- Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
- Mechanism of Action Calcitonin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Postmenopausal osteoporosis
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 20 Jul 2012 The European Medicines Agency recommended that intranasal calcitonin-containing medicines should not be used for osteoporosis. Due to an increased risk of cancer associated with long-term use, calcitonin medicines should only be used for the shortest possible time using the minimum effective dose .
- 14 Nov 2003 ICN Pharmaceuticals is now called Valeant Pharmaceuticals International